Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization.
about
Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro.Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-micro-associated HLA class I heavy chain levels and HLA phenotype.
P2860
Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization.
@en
type
label
Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization.
@en
prefLabel
Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization.
@en
P2093
P4510
P1433
P1476
Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization.
@en
P2093
Filvaroff E
Krishnaswamy S
Taidi-Laskowski B
de Bello W
P304
P356
10.1016/0198-8859(94)90074-4
P577
1994-07-01T00:00:00Z